retatrutide clinical trial sign up Phase 3: TRIUMPH Program Results 2026 Eli Lilly's Phase 3 clinical

Together, this combination does not provide clinical benefit due to similar mechanisms of action (see picture below)

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial

[7] [13] It was approved for use in the European Union in November 2014

Caution This is a hypothesis-generating study and should not be considered a study that answers a question

GLP-1 receptor agonists have a well-established safety profile and significant clinical benefits for the conditions they treat

This weekly schedule is similar to other incretin-based medications used for obesity and metabolic health, making it more convenient than medications that require daily dosing